Closed and automated CAR-T production: a fast, simple workflow for high-dose, high-quality cells

Wednesday 12:30 IST / 15:00 AWST / 16:00 KST / 16:00 JST / 18:00 AEDT / 20:00 NZDT

Sponsor

Closed and automated CAR-T production: a fast, simple workflow for high-dose, high-quality cells

As therapies advance toward commercialization, researchers and manufacturers face increasing pressure to streamline workflows without sacrificing cell yield or quality, especially for core steps of cell activation, virus transduction, and cell expansion.

Traditional CAR T workflows often use manual methods for cell activation and virus transduction, and require additional pre-culture before shifting to an automated expansion system, leading to redundant manual steps, risk of quality inconsistency, and long manufacturing cycle time.

This webinar introduces a protocol offering a significantly shortened manufacturing process timeline by closing and automating cell activation, virus transduction, and cell expansion within a single bioreactor system. Detailed data will be presented demonstrating that the Quantum™ 3-in-1 shortened manufacturing time by 30% compared with manual protocols and achieved over 40% transduction efficiency.

Watch this webinar to learn how to:

Integrate cell activation, virus transduction, and expansion into a single automated, functionally closed bioreactor run—eliminating the need for pre-culture and simplifying the CAR-T workflow
Achieve a 15B cell yield in a serum-free system within 8 days, reducing the manufacturing cycle by 30% compared with manual processes
Preserve 33% more Tscm phenotypes and deliver 2x higher transduction efficiency compared to manual processes

Wenyan Leong

Strategy Lead, APAC and Japan at Terumo

Wenyan currently serves as the Strategy Leader for Cell Therapy Technologies Division in Asia Pacific and Japan, where she drives commercial strategy and growth in automated cell therapy manufacturing.

Wenyan holds a Ph.D. in Biomedical Engineering and has a decade of global experience across multiple commercial roles in different regions. She is committed to seeking active dialogue across different stakeholders throughout the drug development and patient continuum pathways, to accelerate the transformation of cell therapy manufacturing in the regions.

Louise Tan

APAC FAS Supervisor at Terumo

Louise graduated from the world class university- University of Manchester. She took Master in Immunology and PhD in Translational Medicine under School of Medicine. She did research on children skin disease in relation to Staphylococcus aureus. She was a member of the British Society of Immunology. After graduated, Louise worked as a senior research fellow in National University Health System: National University of Singapore (NUS) joint with National University of Hospital (NUH). She continued to pursue her research on translational medicine in the cancer clinicopathological and cancer treatment especially on immune cell therapy- on NK and T cells. She is also one of the collaborators for the Clinical trial Phase 1 on cell therapy for cancer treatment.

in 31

Days